{"id":53620,"date":"2024-10-24T08:00:00","date_gmt":"2024-10-24T06:00:00","guid":{"rendered":"https:\/\/www.stille.se\/us\/mfn_news\/stille-ab-interim-report-q3-2024\/"},"modified":"2024-10-24T08:00:00","modified_gmt":"2024-10-24T06:00:00","slug":"stille-ab-interim-report-q3-2024","status":"publish","type":"mfn_news","link":"https:\/\/www.stille.se\/us\/news\/stille-ab-interim-report-q3-2024\/","title":{"rendered":"Stille AB: Interim Report Q3 2024"},"content":{"rendered":"
\n

Stille AB (publ) today presents the report for the third quarter 2024.<\/strong><\/p>\n<\/div>\n

\n

Revenue amounted to MSEK 127.9 (70.1) driven by strong organic growth in surgical instruments and the successful acquisition of Fehling. Total growth amounted to 82.4 percent, of which 7.4 percent was organic growth.<\/p>\n

\u201cOrganic growth remained robust, despite high comparable figures and slightly lower demand in the surgical table business compared with the same quarter previous year.\u201d<\/em>, says Torbj\u00f6rn Sk\u00f6ld and comments on the company\u2019s revised financial targets \u201cOur revised targets reflect our ambition to constantly improve, challenge ourselves and continue evolving.\u201d.<\/em><\/p>\n

The gross profit margin amounted to 51.8 percent (46.7) and operating profit before non-recurring items amounted to MSEK 23.4 (11.9).<\/p>\n

\u201d2024 has continued on a high note \u2013 our products are delivering value to our customers, which is creating favorable demand, strong growth and a healthy cash flow.\u201d,<\/em> concludes Stille\u2019s CEO.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
MSEK<\/strong><\/td>\nJUL-SEP<\/strong>
<\/strong>2024<\/strong><\/td>\n		JUL-SEP<\/strong>
<\/strong>2023<\/strong><\/td>\n		JAN-SEP<\/strong>
<\/strong>2024<\/strong><\/td>\n		JAN-SEP<\/strong>
<\/strong>2023<\/strong><\/td>\n		OCT-SEP<\/strong>
<\/strong>2023\/24<\/strong><\/td>\n		JAN-DEC<\/strong>
<\/strong>2023<\/strong><\/td>\n<\/tr>\n
Net sales<\/td>\n127.9\u00a0<\/td>\n70.1\u00a0<\/td>\n410.2\u00a0<\/td>\n217.6\u00a0<\/td>\n487.4\u00a0<\/td>\n294.9\u00a0<\/td>\n<\/tr>\n
Gross profit, %<\/td>\n51.8\u00a0<\/td>\n46.7\u00a0<\/td>\n49.8\u00a0<\/td>\n44.6\u00a0<\/td>\n50.1\u00a0<\/td>\n44.8\u00a0<\/td>\n<\/tr>\n
EBITDA before
non-recurring items<\/td>\n		30.2\u00a0<\/td>\n15.5\u00a0<\/td>\n99.9\u00a0<\/td>\n45.0\u00a0<\/td>\n117.5\u00a0<\/td>\n62.6\u00a0<\/td>\n<\/tr>\n
EBITDA before
non-recurring items, %<\/td>\n		23.6\u00a0<\/td>\n22.1\u00a0<\/td>\n24.3\u00a0<\/td>\n20.7\u00a0<\/td>\n24.1\u00a0<\/td>\n21.2\u00a0<\/td>\n<\/tr>\n
EBITDA<\/td>\n30.2\u00a0<\/td>\n15.5\u00a0<\/td>\n79.8\u00a0<\/td>\n41.7\u00a0<\/td>\n97.5\u00a0<\/td>\n59.3\u00a0<\/td>\n<\/tr>\n
EBITDA, %<\/td>\n23.6\u00a0<\/td>\n22.1\u00a0<\/td>\n19.5\u00a0<\/td>\n19.1\u00a0<\/td>\n20.4\u00a0<\/td>\n20.1\u00a0<\/td>\n<\/tr>\n
Operating profit before
non-recurring items<\/td>\n		23.4\u00a0<\/td>\n11.9\u00a0<\/td>\n79.4\u00a0<\/td>\n34.3\u00a0<\/td>\n93.4\u00a0<\/td>\n48.3\u00a0<\/td>\n<\/tr>\n
Operating profit before
non-recurring items, %<\/td>\n		18.3\u00a0<\/td>\n17.0\u00a0<\/td>\n19.4\u00a0<\/td>\n15.8\u00a0<\/td>\n20.0\u00a0<\/td>\n16.4\u00a0<\/td>\n<\/tr>\n
Operating profit<\/td>\n23.4\u00a0<\/td>\n11.9\u00a0<\/td>\n59.4\u00a0<\/td>\n31.0\u00a0<\/td>\n73.3\u00a0<\/td>\n45.0\u00a0<\/td>\n<\/tr>\n
Operating profit, %<\/td>\n18.3\u00a0<\/td>\n17.0\u00a0<\/td>\n14.5\u00a0<\/td>\n14.2\u00a0<\/td>\n15.5\u00a0<\/td>\n15.2\u00a0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Torsh\u00e4lla, October 24th, 2024.<\/p>\n<\/div>\n

\n

This information is information that Stille is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-24 08:00 CEST.<\/em><\/p>\n<\/div>\n

\n

Contact Details<\/strong>
Torbj\u00f6rn Sk\u00f6ld<\/strong>
CEO & President
+46 (0)70 316 63 91 | torbjorn.skold@stille.se<\/a><\/p>\n<\/div>\n

\n

About Us<\/strong>
Stille AB (publ) develops, manufactures and markets medical devices<\/strong> for surgeons across the world. Stille was founded in 1841 and is one of the world\u2019s oldest medical device companies. Stille\u2019s main business areas are surgical instruments and c-arm tables. Stille\u2019s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym \u201cSTIL\u201d with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, adviser@eminova.se. For more information, visit www.stille.se<\/a>.<\/p>\n<\/div>\n

\n

Attachments<\/strong>
Interim Report Q3 2024<\/a><\/p>\n<\/div>\n